Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration…
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure…
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement…
- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral…
Leveraging the Power of Data to Accelerate Scientific Discovery and Improve Health in the Bronx NEW YORK, May 6, 2025…
University of Wisconsin–Madison Research Project Will Investigate Whether Transcranial Electrical Stimulation with Temporal Interference Can Improve the Restorative Nature of…
Presentation of biomarker findings from cerebrospinal fluid analysesWorkshop on adaptive and decentralized ALS trial designPanel on clinical trial access and the…
SAN MATEO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated…
Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing…
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty…
